News
M6P Therapeutics Presents Promising Preclinical Data in Lysosomal Storage Disorders at the 17th Annual WORLDSymposium™ 2021
– Study Results Highlight Potential Utility of Targeting Mannose 6-Phosphate Pathway to Treat Gaucher Disease and Mucolipidosis II – ST. LOUIS, Mo., – Feb. 11, ...
Read More →
M6P Therapeutics Supports Rare Disease Day 2021 and Joins Global Movement to Increase Awareness of Rare Diseases
ST. LOUIS, Mo., – Feb. 25, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal ...
Read More →
M6P Therapeutics Announces Formation of Distinguished, Experienced Scientific Advisory Board
ST. LOUIS, Mo., – Feb. 3, 2021 – M6P Therapeutics, a privately held life sciences company developing next-generation recombinant enzyme and gene therapies for lysosomal ...
Read More →
M6P Therapeutics Receives Six Rare Pediatric Disease Designations from the U.S. FDA for Company’s Deep Pipeline of Programs for Lysosomal Storage Disorders
– U.S. FDA Also Grants Two Orphan Drug Designations for the Company’s Gene Therapy Programs for Gaucher Disease and Mucolipidosis – ST. LOUIS, Mo., – ...
Read More →